HPV Testing & PAP Test Sales are slated to surge at CAGR of 6.8% during the forecast period - Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company

The global HPV testing & PAP test market was valued at USD 3.7 billion in 2022 and it is anticipated to grow further till USD 7.2 billion by 2032, at a CAGR of 6.8% during the forecast period.

To Remain 'Ahead' Of Your Competitors, Request for A Sample -https://www.globalinsightservices.com/request-sample/GIS24644

The most prevalent sexually transmitted infection in the world is caused by the papillomaviridae family's Human Papillomavirus (HPV). A double-stranded DNA tumor virus called the human papillomavirus promotes the growth of epithelial cells on the cutaneous and mucosal surfaces.

HPV is divided into two categories, such as low-risk HPVs and high-risk HPVs, depending on the risk involved. About 14 HPV varieties, including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, are considered high-risk.

Read More Report of HPV Testing & PAP Test Market: https://www.globalinsightservices.com/reports/hpv-testing-pap-test-market/

Cervical and vaginal cancers are now well known to be caused by high-risk strains of the HPV virus. The most oncogenic HPV type, HPV 16, causes over half of all cervical cancers, and HPV 16 and 18 together cause around 70% of cervical cancers.

Market Driver and Trends

The rise in cervical cancer incidences worldwide, the expansion of cervical cancer screening programmes, and the adoption of cutting-edge technology are the market's main growth drivers. The World Health Organization (WHO) estimates that more than 500,000 women will get cervical cancer in 2020, and 342,000 will pass away as a result.

Get A Customized Scope to Match, Your Need Ask an Expert -https://www.globalinsightservices.com/request-customization/GIS24644

In accordance with the World Health Assembly's endorsement of WHO's global strategy for eradicating cervical cancer in 2020, 70% of women worldwide must undergo routine high-performance cervical cancer screenings, and 90% of those who do so must receive the necessary treatment, which may include surgery.

For In-Depth Competitive Analysis, Purchase this Report -https://www.globalinsightservices.com/checkout/single_user/GIS24644

Global HPV Testing & PAP Test Market Segmentation
By Test Type

HPV Test
Pap Test
Co-test
By Application

Cervical Cancer
Vaginal Cancer
By Location of Testing

Hospitals & Clinics
Diagnostic Centers
Others

Major Players in the Global HPV Testing & PAP Test Market
The report analyses various key players such as Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and OncoHealth Corporation among others.

New Report Published by Global Insight Services: https://www.globalinsightservices.com/reports/hydrogen-projects-database/

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.